Clinicopathological Characteristics and Prognosis of 50 Patients with High-grade Gastric Neuroendocrine Malignancies

DENG Yujie; CHEN Xiaohui; LIN Xuede; SHI Xi; ZENG Wucha; ZHENG Min

doi:10.3971/j.issn.1000-8578.2014.10.008

Cancer Research on Prevention and Treatment > 2014 > 41(10): 1093-1097. > DOI: 10.3971/j.issn.1000-8578.2014.10.008

DENG Yujie, CHEN Xiaohui, LIN Xuede, SHI Xi, ZENG Wucha, ZHENG Min. Clinicopathological Characteristics and Prognosis of 50 Patients with High-grade Gastric Neuroendocrine Malignancies[J]. Cancer Research on Prevention and Treatment, 2014, 41(10): 1093-1097. DOI: 10.3971/j.issn.1000-8578.2014.10.008

Citation:

PDF (662 KB)

Clinicopathological Characteristics and Prognosis of 50 Patients with High-grade Gastric Neuroendocrine Malignancies

1. Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005,China;2. Department of Thoracic Surgery, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University

More Information

Received Date: April 29, 2014
Revised Date: July 24, 2014

Graphical Abstract

Abstract

Abstract

Objective To investigate clinicopathological characteristics and prognostic factors of patients with high-grade gastric neuroendocrine malignancies, including gastric neuroendocrine carcinomas (G-NECs) and gastric mixed adenoneuroendocrine carcinomas (G-MANECs). Methods We retrospectively analyzed the clinicopathological data of 50 patients with high-grade gastric neuroendocrine malignancies including 44 G-NECs and 6 G-MANECs in the Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University from Feb. 2009 to Aug. 2013. According to the WHO classification standard for neoplasms of digestive tract in 2010, their histology and immunohistochemical expression of synaptophysin, chromogranin A and CD56 were observed and analyzed. Prognostic factors were investigated on the basis of the follow-up information and survival analysis. Results Overall expression rates of synaptophysin, chromogranin A and CD56 were 98%, 48% and 38%, respectively. Overall median survival was 29 months; 1-, 2- and 3-years survival were 84%, 44% and 10%, respectively. Significant difference was observed between survival of G-NECs and G-MANECs (P<0.0001). Liver metastasis was found more often in G-MANECs (P=0.005). No statistical difference had been observed among the survival of subgroups of G-NECs, i.e., large-cell, small-cell and mixed NECs (P=0.9717). Conclusion The overall prognosis of patients with highgrade gastric neuroendocrine malignancies is unsatisfied, especially with G-MANECs which present more frequently with liver metastasis.
- Stomach,
- Neuroendocrine carcinoma,
- Mixed adenoneuroendocrine carcinoma,
- Prognosis

FullText(HTML)

References (18)

References

[1]	Oberg K. Neuroendocrine tumors (NETs): historical overview and epidemiology[J]. Tumori, 2010, 96(5): 797-801.
[2]	Niederle MB, Hackl M, Kaserer K,et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters[J]. Endocr Relat Cancer, 2010, 17(4): 909-18.
[3]	Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms[J]. Neuroendocrinology, 2012, 95(2): 74 -87.
[4]	Rindi G. The ENETS guidelines: the new TNM classification system[J]. Tumori, 2010, 96(5): 806-9.
[5]	Oberg K, Akerström G, Rindi G, et al. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 20 10, 21 Suppl 5: v223-7.
[6]	Li ZS, Li Q. The latest 2010 WHO classification of tumors of digestive system[J]. Zhonghua Bing Li Xue Za Zhi, 2011, 40(5): 35 1-4. [李增山, 李清. 2010年版消化系统肿瘤WHO分类解读 [J] 中华病理学杂志,2011, 40(5):351-4.]
[7]	Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type highgrade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? [J]. Am J Surg Pathol,2008, 32 (5):719-31.
[8]	Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm[J]. Zhonghua Bing Li Xue Za Zhi, 2011,40(4): 257-62. [ 中国胃肠胰神经内分泌肿瘤病理专家组.中国胃肠胰神经内分泌肿瘤病理学诊断共识[J]. 中华病理学杂志, 2011, 40(4): 257-62.]
[9]	Domori K, Nishikura K, Ajioka Y, et al. Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis[J]. Gastric Cancer, 2014, 17 (2): 263-72.
[10]	Ye YH, Zhang S, Wang XF, et al. Reassessment of pathological diagnosis in 90 cases of gastrointestinal neuroendocrine neoplasm[J]. Huazhong Ke Ji Da Xue Xue Bao(Yi Xue Ban), 20 12, 41(4):440-4. [叶郁红,张声,王行富,等.90例胃肠道神经内分泌肿瘤病理学重新诊断评估[J].华中科技大学学报(医学版) ,2012,41(4):440-4.]
[11]	Ishida M, Sekine S, Fukagawa T, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis[J]. Am J Surg Pathol, 2013, 37(7): 94 9-59.
[12]	Capella C, La Rosa S, Uccella S, et al. Mixed endocrine-exocrine tumors of the gastrointestinal tract[J]. Semin Diagn Pathol, 2000, 17 (2): 91-103.
[13]	Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set[J]. Am J Surg Pathol, 2010, 34(3): 300-13.
[14]	Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems[J]. Pancreas 2010, 39(6): 707-12.
[15]	Zheng J . Standardizat ion in pathologic diagnos i s of gastrointestinal and pancreatic neuroendocrine tumors[J]. Zhonghua Bing Li Xue Za Zhi,2010, 39(12):793-5. [郑杰. 规范胃肠道和胰腺神经内分泌肿瘤的病理诊断[J]. 中华病理学杂志, 20 10, 39(12):793-5.]
[16]	Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors[J]. Endocr Rev, 2004, 25(3): 458-511.
[17]	Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)[J]. Ann Oncol, 2010, 21(9): 1794-803.
[18]	Huang ZG, Xie ZM. Clinicopathological study of neuroendocrine neoplasms of gastrointestinal tracts[J]. Xian Dai Yu Fang Yi Xue, 20 12, 39(19): 5173-5. [黄治国, 谢宗庙. 胃肠道神经内分泌肿瘤 32 例临床及病理分析[J]. 现代预防医学, 2012, 39(19): 5173-5.]

[1]	TANG Wenchao, LI Yuanwei, CHEN Jia, QIN Yipeng, WU Zhiying, FU Huifeng. Prognostic Evaluation of Prognostic Nutrition Index for Patients with Radical Cystectomy: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 871-876. DOI: 10.3971/j.issn.1000-8578.2021.21.0326
[2]	WANG Yan, CAO Yu, YIN Jinhuan, LIU Junfeng. Correlation of Prognostic Nutritional Index with Overall Survival of Postoperative Patients with Thymoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(2): 140-144. DOI: 10.3971/j.issn.1000-8578.2021.20.0651
[3]	WEI Xueyan, HAN Guang, LI Ying, HU Desheng. Effect of Whole-course Nutrition Support on Nutritional Status of Patients with Locally Advanced Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(8): 617-622. DOI: 10.3971/j.issn.1000-8578.2020.20.0432
[4]	LIU Faqiang, LU Xiaolin, CHANG Yingbin. Clinical Effect of Oral Nutritional Supplements in Patients with Colorectal Cancer After Emergency Surgery[J]. Cancer Research on Prevention and Treatment, 2019, 46(7): 610-613. DOI: 10.3971/j.issn.1000-8578.2019.19.0529
[5]	HUANG Jing, SHEN Hongmei, WU Yunli. Effect of Modified Yangyin Qingfei Decoction Combined with Nutritional Intervention on Nutritional Status and Curative Effect of Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2019, 46(2): 159-163. DOI: 10.3971/j.issn.1000-8578.2019.18.0814
[6]	QI Xiaoguang, QI Chunyan, QIN Boyu, WANG Lijie, HU Yi. Comparison of Different Time Nutritional Intervention on Chemotherapy-induced Ⅳ Degree Myelosuppression in Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(1): 29-31. DOI: 10.3971/j.issn.1000-8578.2018.17.0715
[7]	WEI Yujia, YAN Chao, SUN Kejuan, DU Hongzhen, LI Zengning. Nutritional Status of 427 Malignant Tumor Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(1): 19-23. DOI: 10.3971/j.issn.1000-8578.2018.17.0781
[8]	SUN Zhiwei, JIA Jun, YANG Ying, LIU Chuanling, XIAO Yanjie, YU Jing, ZHANG Xiaodong. Correlation of Baseline Nutritional Status with Response to Chemotherapy and Survival of Advanced Esophageal Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(9): 612-617. DOI: 10.3971/j.issn.1000-8578.2017.17.0158
[9]	ZHU Bu-dong, XUE De-liang, LIU Shu-jun, et al. The Evaluation of Nutritional Parameters in Patients with Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(03): 220-221. DOI: 10.3971/j.issn.1000-8578.2143
[10]	Liu-qing YANG, Han-ping SHI. The establishment and innovation of nutrition diagnosis and treatment System for cancer patients in China[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20241268

Cited By

Get Citation

PDF

XML

Article views (1462) PDF downloads (788)

Turn off MathJax

Article Contents

Abstract

References

Clinicopathological Characteristics and Prognosis of 50 Patients with High-grade Gastric Neuroendocrine Malignancies

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Clinicopathological Characteristics and Prognosis of 50 Patients with High-grade Gastric Neuroendocrine Malignancies

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content